|Bid||126.72 x 800|
|Ask||126.68 x 1200|
|Day's range||124.88 - 126.84|
|52-week range||103.13 - 129.70|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||31.44|
|Earnings date||20 Oct 2021|
|Forward dividend & yield||1.80 (1.44%)|
|Ex-dividend date||14 Oct 2021|
|1y target est||137.05|
Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. Abbott provided its third-quarter update before the market opened on Wednesday. Here are three things that investors should love about the healthcare-giant's Q3 results.
Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. For the quarter, Abbott posted year-over-year sales growth of 23%, as its top line landed at $10.9 billion. Collectively, prognosticators tracking the healthcare company estimated that it would earn a bit more than $9.4 billion on the top line and post an adjusted net profit of $0.93.
With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. With me today are Robert Ford, President and Chief Executive Officer; and Bob Funck, Executive Vice President, Finance and Chief Financial Officer.